Pasithea Therapeutics annual return on equity
2022
2023
2024
2025
Pasithea Therapeutics Return on Equity (ROE) Growth & History (KTTA)
Pasithea Therapeutics's return on equity was −58.36% for fiscal 2025.
View full Pasithea Therapeutics company overviewPasithea Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −58.36% | +14.47 pp |
| 2024 | 2024-12-31 | −72.83% | −24.39 pp |
| 2023 | 2023-12-31 | −48.44% | −18.77 pp |
| 2022 | 2022-12-31 | −29.68% | — |
Pasithea Therapeutics quarterly return on equity
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −10.08% | +16.32 pp |
| Q1 2026 | 2026-03-31 | −5.22% | +20.45 pp |
| Q4 2025 | 2025-12-31 | −29.99% | −10.49 pp |
| Q3 2025 | 2025-09-30 | −22.18% | −4.53 pp |
| Q2 2025 | 2025-06-30 | −26.40% | −4.95 pp |
| Q1 2025 | 2025-03-31 | −25.67% | −7.83 pp |
| Q4 2024 | 2024-12-31 | −19.50% | +0.00 pp |
| Q3 2024 | 2024-09-30 | −17.65% | −6.36 pp |
| Q2 2024 | 2024-06-30 | −21.44% | −11.37 pp |
| Q1 2024 | 2024-03-31 | −17.84% | −9.17 pp |
| Q4 2023 | 2023-12-31 | −19.50% | −8.04 pp |
| Q3 2023 | 2023-09-30 | −11.30% | −1.95 pp |
| Q2 2023 | 2023-06-30 | −10.07% | −4.82 pp |
| Q1 2023 | 2023-03-31 | −8.67% | −5.56 pp |
| Q4 2022 | 2022-12-31 | −11.46% | −13.32 pp |
| Q3 2022 | 2022-09-30 | −9.35% | +8.91 pp |
| Q2 2022 | 2022-06-30 | −5.25% | — |
| Q1 2022 | 2022-03-31 | −3.11% | — |
| Q4 2021 | 2021-12-31 | 1.86% | — |
| Q3 2021 · Sep 30 | 2021-09-30 | −18.26% | — |
Pasithea Therapeutics return on equity trends
Between the periods ended 2022-12-31 and 2025-12-31, Pasithea Therapeutics's return on equity decreased from −29.68% to −58.36%, a change of −28.69 percentage points. The latest reported quarter, Q2 2026, shows −10.08%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pasithea Therapeutics source filings ↗